Lakshmi Nayak
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lakshmi Nayak as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:16 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07710131 · Neurocognitive Assessment CNSL and LGGDana-Farber Cancer Institute · not yet recruiting · PCNSL, Brain Tumor, Cognitive Dysfunction · principal investigator
- Ph1NCT06475235 · Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLDana-Farber Cancer Institute · recruiting · Lymphoma, Primary Central Nervous System Lymphoma · principal investigator
- Ph2NCT04906096 · Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLLakshmi Nayak, MD · recruiting · Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site · principal investigator
- Ph1/Ph2NCT04906902 · Acalabrutinib in CNSLDana-Farber Cancer Institute · active not recruiting · Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma, Recurrent Central Nervous System Lymphoma · principal investigator
- Ph1/Ph2NCT04421560 · Pembrolizumab, Ibrutinib and Rituximab in PCNSLDana-Farber Cancer Institute · recruiting · Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer · principal investigator
- Ph1NCT02142803 · TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsNational Cancer Institute (NCI) · active not recruiting · Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026Named on NCT02142803
- U01CA062490RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT02142803
- U01CA076576RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT02142803
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNUM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2019 to 2026Named on NCT02142803
- The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials NetworkUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2019 to 2026Named on NCT02142803
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:16 UTC. The ranking covers the 200 most relevant of 32 PubMed records, and a shared surname and initials can bring in a namesake. All 32 on PubMed
- 513 citationsRCR 15.2
- 256 citationsRCR 20.9
- Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.Clin Cancer Res · 2021236 citationsRCR 12.8
- Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.J Clin Oncol · 2019146 citationsRCR 5.1
- Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.Nat Med · 2020128 citationsRCR 5.0
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.Neuro Oncol · 2015109 citationsRCR 3.3
- Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.Neuro Oncol · 202286 citationsRCR 6.7
- 65 citationsRCR 4.8
- Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.Leuk Lymphoma · 201364 citationsRCR 2.1
- 62 citationsRCR 2.3